In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Synergetics extends Stryker deal, ends suit

This article was originally published in Clinica

Executive Summary

O'Fallon, Missouri-based Synergetics USA has extended its exclusive worldwide agreement with Stryker for the distribution of its radiofrequency generator for the percutaneous treatment of pain. The original five-year agreement was due to end December 31 2009 but has now been prolonged by an extra year. The contract renewal also includes an increased minimum purchase obligation for each remaining year. The Stryker collaboration provided Synergetics with about $2m in sales for the nine months ended April 30 2007, approximately 6% of total sales for the period. Separately, Synergetics has announced that a US court has dismissed two former employees' claim to vacate a post-judgement motion made in favour of the company relating to allegations that they interfered in the company's business relationships (see Clinica No 1175, p 16). However, the court agreed with Charles Hurst and Michael McGowan's claims that Synergetics had engaged in "improper pre-trial conduct", and awarded them $1.17m in sanctions, which Synergetics will draw out of the original damages of $2.35m.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049574

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel